These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 24716538

  • 1. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
    Sánchez-García J, Del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, Xicoy B, Valcárcel D, Brunet S, Marco-Betes V, García-Pintos M, Osorio S, Tormo M, Bailén A, Cerveró C, Ramos F, Diez-Campelo M, Such E, Arrizabalaga B, Azaceta G, Bargay J, Arilla MJ, Falantes J, Serrano-López J, Sanz GF, Spanish Group on Myelodysplastic Syndromes (GES MD).
    Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
    [Abstract] [Full Text] [Related]

  • 2. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B.
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
    Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U, International Working Group on MDS with del(5q).
    Leukemia; 2013 Apr; 27(5):1072-9. PubMed ID: 23257782
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
    Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, Selleslag D, Beyne-Rauzy O, te Boekhorst P, del Cañizo C, Guerci-Bresler A, Nilsson L, Lübbert M, Quesnel B, Ganser A, Bowen D, Schlegelberger B, Göhring G, Fu T, Benettaib B, Hellström-Lindberg E, Fenaux P.
    Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
    Wu L, Li X, Xu F, Zhang Z, Chang C, He Q.
    Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
    [Abstract] [Full Text] [Related]

  • 13. Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
    Butrym A, Lech-Maranda E, Patkowska E, Kumiega B, Bieniaszewska M, Mital A, Madry K, Torosian T, Wichary R, Rybka J, Warzocha K, Mazur G.
    BMC Cancer; 2015 Jul 08; 15():508. PubMed ID: 26152663
    [Abstract] [Full Text] [Related]

  • 14. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
    Oliva EN, Lauseker M, Aloe Spiriti MA, Poloni A, Cortelezzi A, Palumbo GA, Balleari E, Sanpaolo G, Volpe A, Ricco A, Ronco F, Alati C, D'Errigo MG, Santacaterina I, Kündgen A, Germing U, Latagliata R.
    Cancer Med; 2015 Dec 08; 4(12):1789-97. PubMed ID: 26376955
    [Abstract] [Full Text] [Related]

  • 15. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D, Cannas G, Baracco F, Prebet T, Vey N, Banos A, Besson C, Corm S, Blanc M, Slama B, Perrier H, Fenaux P, Wattel E, Groupe Francophone des Myélodysplasies.
    Br J Haematol; 2012 Mar 08; 156(5):619-25. PubMed ID: 22211483
    [Abstract] [Full Text] [Related]

  • 16. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP.
    Am J Hematol; 2008 Sep 08; 83(9):708-13. PubMed ID: 18634051
    [Abstract] [Full Text] [Related]

  • 17. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
    Le Bras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Banos A, Blanc M, Vey N, Schmidt A, Visanica S, Eclache V, Turlure P, Beyne-Rauzy O, Guerci A, Delmer A, de Botton S, Rea D, Fenaux P, Adès L.
    Leuk Res; 2011 Nov 08; 35(11):1444-8. PubMed ID: 21715006
    [Abstract] [Full Text] [Related]

  • 18. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A.
    Clin Lymphoma Myeloma; 2009 Nov 08; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [Abstract] [Full Text] [Related]

  • 19. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.
    Kurtin SE, List AF.
    Clin Lymphoma Myeloma; 2009 Jun 08; 9(3):E10-3. PubMed ID: 19525184
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.